Cover Image

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did no...

Full description

Saved in:
Bibliographic Details
Main Authors: Premkumar, Vikram (Author) , Lentzsch, Suzanne (Author) , Pan, Samuel (Author) , Bhutani, Divaya (Author) , Richter, Joshua (Author) , Jagannath, Sundar (Author) , Liedtke, Michaela (Author) , Jaccard, Arnaud (Author) , Wechalekar, Ashutosh D. (Author) , Comenzo, Raymond (Author) , Sanchorawala, Vaishali (Author) , Royer, Bruno (Author) , Rosenzweig, Michael (Author) , Valent, Jason (Author) , Schönland, Stefan (Author) , Fonseca, Rafael (Author) , Wong, Sandy (Author) , Kapoor, Prashant (Author)
Format: Article (Journal)
Language:English
Published: 11 January 2021
In: Blood cancer journal
Year: 2021, Volume: 11, Issue: 1, Pages: 1-10
ISSN:2044-5385
DOI:10.1038/s41408-020-00397-w
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41408-020-00397-w
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41408-020-00397-w
Get full text
Author Notes:Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong and Prashant Kapoor
Description
Summary:Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did not, and one t(11;14) status was unknown. Patients received a venetoclax-containing regimen for at least one 21- or 28-day cycle; the median prior treatments was three. The hematologic response rate for all patients was 68%; 63% achieved VGPR/CR. t(11;14) patients had higher hematologic response (81% vs. 40%) and higher VGPR/CR rate (78% vs. 30%, odds ratio: 0.12, 95% CI 0.02-0.62) than non-t(11;14) patients. For the unsegregated cohort, median progression-free survival (PFS) was 31.0 months and median OS was not reached (NR). For t(11;14), median PFS was NR and for non-t(11;14) median PFS was 6.7 months (HR: 0.14, 95% CI 0.04-0.53). Multivariate analysis incorporating age, sex, prior lines of therapy, and disease stage suggested a risk reduction for progression or death in t(11;14) patients. Median OS was NR for either subgroup. The organ response rate was 38%; most responders harbored t(11;14). Grade 3 or higher adverse events occurred in 19% with 7% due to infections. These promising results require confirmation in a randomized clinical trial.
Item Description:Gesehen am 09.03.2021
Physical Description:Online Resource
ISSN:2044-5385
DOI:10.1038/s41408-020-00397-w

Similar Items